Lorigerlimab

DB18942InvestigationalProtein Based Therapies

Lorigerlimab is under investigation in clinical trial NCT05848011 (A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-resistant Prostate Cancer).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death protein 1
Curator reviewed
Also known as: IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS CLONE MG13.78 .KAPPA.-CHAIN V-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGGSGGGG) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEI · MMUNOGLOBULIN G4 SCFV-H-CH2-CH3_SCFV, ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD1, PD-1, CD279)) AND ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), CHIMERIC, HOMO SAPIENS AND HUMANIZED MONOCLONAL ANTIBODY, TET
Code names: AEX-1344 · MGD 019

Resolves to

Compound

UNIIJM802R57SACAS2416595-46-3

Targets

P16410CTLA4Q15116PDCD1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lorigerlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account